J&J's Children's Motrin to get advisory committee review.
This article was originally published in The Tan Sheet
Executive Summary
J&J's CHILDREN's MOTRIN TO GET ADVISORY COMMITTEE REVIEW as part of the Nonprescription Drugs Advisory Committee's agenda for its March 27-28 meeting. On the morning of March 28, NDAC with FDA's Arthritis Advisory Committee will consider J&J's application covering the OTC marketing of the pediatric ibuprofen suspension product.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning